Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Clinical Trials Using Immunotoxin D2C7-(scdsFv)-PE38KDEL

Review the clinical trials studying immunotoxin d2c7-(scdsfv)-pe38kdel on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-3 of 3

Intratumoral 2141-V11 and D2C7-IT for the Treatment of Recurrent Malignant Gliomas
Status: Active
Location: Duke University Medical Center, Durham, North Carolina
D2C7-IT and 2141-V11 Given via Convection Enhanced Delivery Followed by 2141-V11 via Cervical Perilymphatic Subcutaneous Injections for the Treatment of Recurrent Glioblastoma
Status: Active
Location: Duke University Medical Center, Durham, North Carolina
Intracerebral Delivery of D2C7-IT and 2141-V11 in Residual Disease and Perilymphatic Subcutaneous Injections of 2141-V11 for the Treatment of Newly Diagnosed MGMT Unmethylated Glioblastoma
Status: Active
Location: Duke University Medical Center, Durham, North Carolina